

Table S1. RBD-specific antibodies, % inhibition, and seroconversion rate against WT-SARS-CoV-2

Time point	Anti-spike RBD (BAU/mL) (median, IQR)		P-value	% Inhibition (median, IQR)		P-value	Seroconversion rate (n, %)		P-value
	AZD1222/ mRNA1273 (N=92)*	BNT162b2/ mRNA1273 (N=16)		AZD1222/ mRNA1273 (N=92)*	BNT162b2/ mRNA1273 (N=16)		AZD1222/ mRNA1273 (N=92)*	BNT162b2/ mRNA1273 (N=16)	
<i>Overall</i>									
Before the 3 rd dose	48.9 (40.4, 59.0)	49.4 (30.4, 80.3)	0.964	30.3 (17.6, 45.2)	23.4 (10.0, 47.5)	0.324	46 (50.0)	6 (37.5)	0.356
4-week after the 3 rd dose	1,227.4 (1,078.8, 1,396.5)	2,437.4 (1,803.2, 3,294.8)	<0.001	98.4 (97.8, 98.5)	98.6 (98.4, 98.7)	0.005	91 (98.9)	16 (100.0)	1.000
Before the 4 th dose	249.4 (212.5, 292.7)	369.5 (267.4, 510.6)	0.056	87.5 (64.3, 95.7)	92.6 (81.9, 97.5)	0.102	90 (97.8)	16 (100.0)	1.000
4-week after the 4 th dose	5,121.7 (4,640.1, 5,653.3)	3,700.4 (3,001.4, 4,562.2)	0.011	98.2 (98.0, 98.3)	98.2 (98.0, 98.4)	0.305	89 (98.9)	16 (100.0)	1.000
<i>Duration from the 2nd dose ≤ 90 days</i>									
Before the 3 rd dose	69.1 (57.2, 83.4)	82.7 (52.9, 129.3)	0.469	32.7 (18.6, 49.9)	39.4 (23.8, 52.6)	0.498	36 (59.0)	6 (60.0)	0.953
4-week after the 3 rd dose	1,169.3 (1,004.4, 1,361.3)	2,635.5 (1,619.1, 4,290.0)	0.002	98.4 (97.6, 98.5)	98.6 (98.4, 98.7)	0.004	61 (100.0)	10 (100.0)	-
Before the 4 th dose	224.9 (186.5, 271.2)	344.0 (210.9, 561.3)	0.090	86.4 (61.2, 95.7)	91.7 (70.3, 97.5)	0.209	60 (98.4)	10 (100.0)	1.000
4-week after the 4 th dose	5,097.7 (4,496.4, 5,779.3)	4,311.6 (3,197.9, 5,813.1)	0.308	98.2 (97.9, 98.3)	98.3 (98.1, 98.4)	0.075	60 (100.0)	10 (100.0)	-
<i>Duration from the 2nd dose > 90 days</i>									
Before the 3 rd dose	24.7 (18.1, 33.7)	20.9 (11.0, 40.0)	0.653	21.7 (17.2, 35.7)	4.6 (1.1, 12.6)	0.002	10 (32.3)	0 (0.0)	0.162
4-week after the 3 rd dose	1,350.3 (1,053.3, 1,731.2)	2,139.9 (1,555.9, 2,943.0)	0.114	98.4 (98.1, 98.5)	98.5 (98.3, 98.7)	0.364	30 (96.8)	6 (100.0)	1.000
Before the 4 th dose	305.6 (225.9, 413.5)	416.2 (250.2, 692.4)	0.384	88.5 (70.5, 95.7)	94.0 (86.8, 97.5)	0.342	30 (96.8)	6 (100.0)	1.000
4-week after	5,170.1	2,868.2	0.004	98.2	98.0	0.496	29	6	1.000

the 4 th dose	(4,371.4, 6,114.8)	(2,434.3, 3,379.4)		(98.1, 98.3)	(97.7, 98.4)		(96.7)	(100.0)	
--------------------------	--------------------	--------------------	--	--------------	--------------	--	--------	---------	--

*N=90 for participants at 4 weeks after the fourth dose